Učitavanje...
The evolving role of Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia
Ibrutinib, the first in class of the oral covalent Bruton tyrosine kinase (BTK) inhibitors, has profoundly changed the treatment landscape of chronic lymphocytic leukemia (CLL). The phase III RESONATE and RESONATE-2 trials first demonstrated the superiority of ibrutinib over ofatumumab in the relaps...
Spremljeno u:
| Izdano u: | Ther Adv Hematol |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
SAGE Publications
2021
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7970705/ https://ncbi.nlm.nih.gov/pubmed/33796237 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620721989588 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|